- Home
- AMGN vs BKNG Comparison
AMGN vs BKNG Comparison
Compare AMGN & BKNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- BKNG
- Stock Information
- Founded
- AMGN 1980
- BKNG 1997
- Country
- AMGN United States
- BKNG United States
- Employees
- AMGN N/A
- BKNG N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- BKNG Transportation Services
- Sector
- AMGN Health Care
- BKNG Consumer Discretionary
- Exchange
- AMGN Nasdaq
- BKNG Nasdaq
- Market Cap
- AMGN 156.2B
- BKNG 149.0B
- IPO Year
- AMGN N/A
- BKNG 1999
- Fundamental
- Price
- AMGN $265.86
- BKNG $5,072.54
- Analyst Decision
- AMGN Buy
- BKNG Buy
- Analyst Count
- AMGN 19
- BKNG 30
- Target Price
- AMGN $324.37
- BKNG $5,324.48
- AVG Volume (30 Days)
- AMGN 2.7M
- BKNG 245.6K
- Earning Date
- AMGN 05-01-2025
- BKNG 04-29-2025
- Dividend Yield
- AMGN 3.58%
- BKNG 0.76%
- EPS Growth
- AMGN 56.16
- BKNG 20.24
- EPS
- AMGN 10.94
- BKNG 161.59
- Revenue
- AMGN $34,126,000,000.00
- BKNG $24,086,000,000.00
- Revenue This Year
- AMGN $7.19
- BKNG $8.24
- Revenue Next Year
- AMGN $2.37
- BKNG $8.38
- P/E Ratio
- AMGN $24.29
- BKNG $31.44
- Revenue Growth
- AMGN 15.56
- BKNG 9.47
- 52 Week Low
- AMGN $253.30
- BKNG $3,180.00
- 52 Week High
- AMGN $346.85
- BKNG $5,337.24
- Technical
- Relative Strength Index (RSI)
- AMGN 34.80
- BKNG 60.15
- Support Level
- AMGN $268.81
- BKNG $5,132.62
- Resistance Level
- AMGN $291.61
- BKNG $5,238.34
- Average True Range (ATR)
- AMGN 7.54
- BKNG 129.00
- MACD
- AMGN -0.76
- BKNG 29.97
- Stochastic Oscillator
- AMGN 0.76
- BKNG 77.62
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About BKNG Booking Holdings Inc.
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, Rentalcars.com, Kayak, and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.